BioCentury | Feb 3, 2014
Company News

Sorbent management update

...Business: Renal, Cardiovascular Hired: Tom O'Neil as CFO, formerly VP of finance and administration at ChemGenex Pharmaceuticals Ltd....
BioCentury | Jun 4, 2012
Clinical News

Omacetaxine mepesuccinate regulatory update

...through its acquisition of Cephalon Inc. last year. Cephalon had rights through its acquisition of ChemGenex Pharmaceuticals Ltd....
BioCentury | May 28, 2012
Company News

Talon Therapeutics management update

...DeZao as head of commercial operations and planning, formerly SVP and chief commercial officer at ChemGenex Pharmaceuticals Ltd....
BioCentury | Feb 13, 2012
Company News

Sunesis management update

...Hired: Adam Craig as EVP of development and CMO, effective March 1, formerly CMO of ChemGenex Pharmaceuticals Ltd....
BioCentury | Jan 16, 2012
Emerging Company Profile

NewGen: Compositions matter

...The former senior executives of ChemGenex Pharmaceuticals Ltd. have reunited to build another cancer company - NewGen Therapeutics...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

...NASDAQ:CHTP)/Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) Northera droxidopa Neurogenic orthostatic hypotension Submit NDA 3Q11 ChemGenex Pharmaceuticals Ltd....
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Cancer

...BCL2) and MCL1 inhibitor that is in Phase I/II and Phase II testing for cancer. ChemGenex Pharmaceuticals Ltd....
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...BCL2) and MCL1 inhibitor that is in Phase I/II and Phase II testing for cancer. ChemGenex Pharmaceuticals Ltd....
BioCentury | Apr 4, 2011
Strategy

Half-A-Loaf Dilemma

...the beginning of 2009, including proposals to buy cancer plays Gemin X Pharmaceuticals Inc. and ChemGenex Pharmaceuticals Ltd....
...plc (LSE:AZN; NYSE:AZN), London, U.K. Bayer AG (Xetra:BAY), Leverkusen, Germany Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. ChemGenex Pharmaceuticals Ltd....
BioCentury | Apr 4, 2011
Finance

Highlights of weekly biotech stock moves

...NYSE and gained C$7.33 (17%) to C$51.37 in Toronto (see "Half-a-loaf Dilemma," A19) . Separately, ChemGenex Pharmaceuticals Ltd....
Items per page:
1 - 10 of 121
BioCentury | Feb 3, 2014
Company News

Sorbent management update

...Business: Renal, Cardiovascular Hired: Tom O'Neil as CFO, formerly VP of finance and administration at ChemGenex Pharmaceuticals Ltd....
BioCentury | Jun 4, 2012
Clinical News

Omacetaxine mepesuccinate regulatory update

...through its acquisition of Cephalon Inc. last year. Cephalon had rights through its acquisition of ChemGenex Pharmaceuticals Ltd....
BioCentury | May 28, 2012
Company News

Talon Therapeutics management update

...DeZao as head of commercial operations and planning, formerly SVP and chief commercial officer at ChemGenex Pharmaceuticals Ltd....
BioCentury | Feb 13, 2012
Company News

Sunesis management update

...Hired: Adam Craig as EVP of development and CMO, effective March 1, formerly CMO of ChemGenex Pharmaceuticals Ltd....
BioCentury | Jan 16, 2012
Emerging Company Profile

NewGen: Compositions matter

...The former senior executives of ChemGenex Pharmaceuticals Ltd. have reunited to build another cancer company - NewGen Therapeutics...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

...NASDAQ:CHTP)/Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) Northera droxidopa Neurogenic orthostatic hypotension Submit NDA 3Q11 ChemGenex Pharmaceuticals Ltd....
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Cancer

...BCL2) and MCL1 inhibitor that is in Phase I/II and Phase II testing for cancer. ChemGenex Pharmaceuticals Ltd....
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...BCL2) and MCL1 inhibitor that is in Phase I/II and Phase II testing for cancer. ChemGenex Pharmaceuticals Ltd....
BioCentury | Apr 4, 2011
Strategy

Half-A-Loaf Dilemma

...the beginning of 2009, including proposals to buy cancer plays Gemin X Pharmaceuticals Inc. and ChemGenex Pharmaceuticals Ltd....
...plc (LSE:AZN; NYSE:AZN), London, U.K. Bayer AG (Xetra:BAY), Leverkusen, Germany Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. ChemGenex Pharmaceuticals Ltd....
BioCentury | Apr 4, 2011
Finance

Highlights of weekly biotech stock moves

...NYSE and gained C$7.33 (17%) to C$51.37 in Toronto (see "Half-a-loaf Dilemma," A19) . Separately, ChemGenex Pharmaceuticals Ltd....
Items per page:
1 - 10 of 121